The Brief – January 2024

Abstract

Thursday, January 4, 2024 – Published once each month. 2024: The World at Crossroads—Part One Foundational Decisions …

The Brief – January 2024 Read More »

Best practices, technology, and new takes on critical business topics from ChainLink Research

Thursday, January 4, 2024 – Published once each month.

Vital decisions being made in 2024 will affect all of humanity, in arenas such as the battle between democracy vs. autocracy, the future impact of AI on mankind, and the fight against disinformation and runaway partisanship/tribalism. In this first article in the series, we focus on AI, which is poised to provide enormous benefits for mankind. At the same time, it presents serious known issues right now; and extremely-high-consequence but much more speculative risks in the future. Here we discuss why 2024 will be a pivotal year, setting the direction for how mankind addresses those near-term issues and longer-term risks, with implications for decades to come.
[ Read: 2024: The World at Crossroads—Part One ]


Maritime Risk Remains High for Global Supply Chains Heading into 2024

By Matthew York (guest Author)

Thursday, January 4, 2024

As we begin 2024, the global economy faces heightened maritime risk vis-à-vis climate and geopolitical crises in the Panama Canal Zone, Red Sea, and Baltic Sea, on top of persistent maritime risks in the Middle East, East Asia, and Arctic Circle. Supply chain procurement leaders need to implement strategies and best practices to improvise, adapt, and overcome disruptions to global supply chains and shipping capacity in order to drive resilience through the global economy in 2024.
[ Read: Maritime Risk Remains High for Global Supply Chains Heading into 2024 ]


Quantifying the Value of Blockchain-Based Supply Chain Networks—Part Four

Quantify the Value of Patient Adherence and Ease of Doing Business for Pharmaceutical Manufacturers

Thursday, January 4, 2024

We estimate the value that a multi-enterprise supply chain network could potentially provide via patient adherence and ease of doing business improvements. The value is quantified for a hypothetical archetypal pharmaceutical manufacturer. We elucidate the key metrics improved, mechanisms of improvement, and typical improvement range expected.
[ Read: Quantifying the Value of Blockchain-Based Supply Chain Networks—Part Four ]

Scroll to Top